Burke Therapeutics Signs Exclusive Marketing and Supply Agreement with Coeptis Pharmaceuticals for Consensi®


 

HOT SPRINGS -- Burke Therapeutics, a commercial stage pharmaceutical company, has announced it has signed an exclusive marketing and supply agreement with Coeptis Pharmaceuticals, Inc. for the U.S. market. Burke will market the fixed-dose combination drug, Consensi®, a prescription medicine for adults who need both treatment with amlodipine for hypertension, to lower blood pressure, and celecoxib for the management of the signs and symptoms of osteoarthritis. Commercial launch is anticipated in June of 2020.

Consensi is a fixed-dose combination of amlodipine besylate, a calcium channel blocker for the treatment of hypertension, to lower blood pressure, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) for the management of the signs and symptoms of osteoarthritis. The U.S. Food & Drug Administration (FDA) approved Consensi oral tablets for marketing on May 31, 2018.

Consensi is indicated for adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate. Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal CV events, primarily strokes and myocardial infarctions. Celecoxib is indicated for the management of the signs and symptoms of osteoarthritis.

 
Share:

Related Articles:


Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: